Global Urology Device Market Report Reveals Key Trends Driving Outpatient Growth and Disposable Device Adoption

VANCOUVER, BC, March 27, 2025 /PRNewswire/ – A new Global Urological Device Market Report offers critical insights for CEOs, CFOs, product and marketing managers in the medical device industry, helping them identify revenue streams, mitigate risks, and respond strategically to an increasingly dynamic and competitive urological market.

Produced by iData Research, a leading medical consulting and market research firm, this urology-focused report delivers an in-depth analysis of technological innovation, market shifts, and emerging trends that are influencing profitability across the global urological landscape.

“The urology device market is undergoing a transformation, outpatient procedures are becoming the norm, minimally invasive treatments are gaining traction, and single-use scopes are redefining efficiency,” said Dr. Kamran Zamanian, CEO of iData Research. “This report gives urology market leaders the insights they need to adapt to the outpatient shift, seize growth in single-use scopes, and stay competitive in high-demand segments like catheters and BPH treatment.”

The Rise of Outpatient Urology & Disposable Device Innovation

The urological device market is undergoing major shifts as procedures like laser-based BPH treatments move from operating rooms to outpatient settings, driven by better reimbursement and faster recovery times. At the same time, innovations like Boston Scientific’s LithoVue™ have accelerated adoption of single-use ureteroscopes, reducing reprocessing costs and scope damage. Companies such as Ambu are expanding this trend with disposable cystoscopes, improving efficiency and lowering infection risk.

In 2024, the global urological device market surpassed $9.2 billion, driven largely by high-volume urinary catheter usage and is expected to exceed $13.8 billion by 2030. Intermittent catheter use continues to rise, especially for patients managing chronic neurological and urological conditions at home.

The Global Urological Device Market Report includes insights from 65+ countries across 7 key regions, including North America, Latin America, Western Europe, Central & Eastern Europe, the Middle East, Asia-Pacific, and Africa.

Key Insights from the Report:

• Market Risk Assessment: Understand how trends in outpatient care and scope technology disrupt traditional urology business models.
• Pricing Trends: Explore pricing dynamics across urinary catheters, BPH treatments, urological endoscopes, and stone management devices.
• Revenue Opportunities: Discover untapped segments including home-use intermittent catheters and men’s reproductive health tech.
• Competitive Analysis: Benchmark major players like Boston Scientific, Ambu, Teleflex, Coloplast, Olympus, and Cook Medical.
• Regional Growth Hotspots: Uncover high-growth markets influenced by healthcare infrastructure upgrades and policy shifts.
• Technology Trends: Examine the growing impact of single-use scopes, outpatient care preferences, and minimally invasive treatments.

Who Should Read This Report?

This report is designed for CEOs, CFOs, product and marketing managers, as well as strategic decision-makers looking to gain an edge in the growing global urological device sector.

Explore the Market Report

Access a Complimentary Sample of the Full Global Urological Device Market Report, or contact the team at marketing@idataresearch.net to explore strategic insights and growth opportunities.

About iData Research

iData Research has been a leader in market intelligence for the medical device industry for over 20 years, delivering data-driven insights that help companies mitigate market risks, optimize pricing strategies, and uncover new revenue opportunities.

Learn more at https://idataresearch.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/global-urology-device-market-report-reveals-key-trends-driving-outpatient-growth-and-disposable-device-adoption-302412892.html

SOURCE iData Research Inc.